Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6Rituximab 5blinatumomab 4Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Bone Marrow Transplantation 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia, Lymphoid × forodesine × Clear all
NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡